Braxia Scientific Corp

Information

Braxia Scientific, headed by one of the world's leading depression researchers, aims to treat people with depression and debilitating mental illnesses by revolutionizing global mental healthcare practices and developing the next generation of novel ketamine and psychedelic treatments, and delivery systems, through a growing network of Braxia clinics. Through the Braxia Institute, principals have launched various training programs to develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective ketamine and psilocybin-assisted therapy for patients with depression.  

BRAXIA = Brain + Ataraxia  

Braxia Scientific is headed by a world leading researcher in depression research, based on publications in peer-reviewed journals (+700 publications and +30 publications in the space of psychedelics). Braxia Health comprises a growing network of clinics providing ketamine and other psychedelic therapy to patients. Research infrastructure co-localized with clinics facilitate efficient and high quality early proof-of-concept research being sought by large pharma. Braxia also endeavors to synthesize and develop its own IP capable new chemical entities (NCEs) for the treatment of depression and related disorders using proprietary delivery systems. Additionally, the Company maintains extensive relationships with international pharmaceutical companies such as Otsuka, Lundbeck, Pfizer, and AstraZeneca. Braxia recently announced it has received full funding by the Canadian Government for the largest study of its kind with IV Ketamine to be conducted in people living with bipolar disorder, a leading cause of treatment-resistant depression and suicidality. 

Social media

Contact details

Sessions

Videos

Documents & Links

Team

Log in